Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-10-28FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for RENFLEXIS (infliximab) submitted by Organon LLC. The approval updates the product labeling to re…
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs [Phase 3]
Phase 3 study comparing deucravacitinib to placebo in biologic disease-modifying anti-rheumatic drug-naïve patients with active psoriatic ar…
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
EMA approval · 2025-10-21EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Idacio, a biosimilar of adalimumab, for multiple inflammatory diseases, produced by Fresenius Kabi Deutschland GmbH. The indi…
-
FDA approval · 2025-10-17FDA Approved: HADLIMA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-10-17EMA Authorised: Arava (leflunomide) — Sanofi-aventis Deutschland GmbH
The European Medicines Agency authorised Arava (leflunomide) for the treatment of rheumatoid arthritis and psoriatic arthritis, with Sanofi-…
-
FDA approval · 2025-10-16FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XELJANZ (tofacitinib) filed by Pfizer Laboratories Div Pfizer Inc, resulting in changes to t…
-
FDA approval · 2025-10-16FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
FDA approved a supplemental application for Amjevita (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment [Phase 3]
Phase 3 trial comparing secukinumab with ustekinumab in adults with active psoriatic arthritis after TNFα-inhibitor failure has completed an…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity [NA]
This document provides an update on a rheumatology-focused clinical trial sponsored by Brigham and Women's Hospital that studies an adaptive…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice
Pfizer-sponsored clinical trial update shows real-world effectiveness of tofacitinib for psoriatic arthritis in routine clinical practice. R…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients [Phase 3]
Phase 3 trial comparing guselkumab to golimumab in psoriatic arthritis patients who are inadequate responders to TNF inhibitors; currently r…
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases [NA]
Clinical trial update on a high-touch, low-cost approach to improving mental health outcomes in patients with psoriatic diseases; the study …
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: SWE to Detect Enthesitis in PsA: Relationship With SIRT2 Expression and Disease Activity
The update describes a clinical study evaluating using Shear Wave Elastography to detect entheseal involvement in psoriatic arthritis and it…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
A clinical trial from Peking University People's Hospital evaluating mass spectrometry-based immune profiling across autoimmune diseases; th…
-
FDA approval · 2025-09-17FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental BLA for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited. The action concerns regulatory approval rel…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases [Phase 4]
Phase 4 trial assessing dose reduction of Janus kinase inhibitors in inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
A recruiting clinical trial evaluating treatment effectiveness in axial spondyloarthritis and psoriatic arthritis patients starting one of f…
-
EMA withdrawal · 2025-09-08EMA Withdrawn: Eksunbi (ustekinumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn Eksunbi (ustekinumab) from the European market as of 23 May 2025, affecting indications for Crohn's disease, ulcerativ…
-
FDA approval · 2025-09-03FDA Approved: INFLECTRA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Inflectra (infliximab-dyyb) from Pfizer to update its labeling and/or indications, following…
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions
A clinical trial update reports on the use of apremilast in patients with psoriatic arthritis under practice-like conditions. The study NCT0…
-
CLINICAL_TRIALS trial_result · 2025-09-02Clinical Trial Update: Follow-up Evaluating Clinical and Radiological Outcomes of Total Shoulder Arthroplasty With Permedica's MIRAI Prosthesis
Follow-up results from a completed clinical trial assessing the MIRAI total shoulder prosthesis, reporting clinical and radiological outcome…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers [Phase 4]
This multi-center Phase 4 trial is evaluating personalized precision medicine for psoriasis and psoriatic arthritis, with an investigation o…
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
This clinical trial update describes ongoing research in safety and efficacy assessment for rheumatologic diseases and related conditions, w…